H-ASGPGGGAPR-OH
Ref. 3D-PP47691
| 1mg | 232.00 € | ||
| 10mg | 273.00 € | ||
| 100mg | 497.00 € |
Product Information
Peptide H-ASGPGGGAPR-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ASGPGGGAPR-OH include the following: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames RF Wang, SL Johnston, G Zeng - The journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/7/3596/7210 Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members KT Hogan, JN Sutton , KU Chu, JAC Busby - Cancer Immunology , 2005 - Springerhttps://link.springer.com/article/10.1007/s00262-004-0592-y MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA KA Chianese-Bullock, J Pressley, C Garbee - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/5/3080/36807 Peptide vaccination in montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T E Clancy-Thompson, LK King, LD Nunnley - Cancer immunology , 2013 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/1/5/332/466869 Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial CL Slingluff Jr , GR Petroni , WC Olson - cancer research: an , 2009 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778314/ Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a CL Slingluff Jr , GR Petroni , WC Olson, ME Smolkin - Clinical Cancer , 2009 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/15/22/7036/74944 Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting CL Slingluff Jr , GR Petroni , KA Chianese-Bullock - Clinical Cancer , 2007 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/13/21/6386/13057 Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines CL Slingluff , GR Petroni , ME Smolkin - Journal of , 2010 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2010/07000/immunogenicity_for_cd8__and_cd4__t_cells_of_2.8.aspx Cancer/testis antigens: structural and immunobiological properties AF Kirkin, KN Dzhandzhugazyan, J Zeuthen - Cancer investigation, 2002 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1081/CNV-120001150 Recognition of human tumours: cancer/testis antigens AF Kirkin, KN Dzhandzhugazyan, J Zeuthen - Cancer Immunology, 2001 - Springerhttps://link.springer.com/content/pdf/10.1007/978-94-017-0963-7.pdf#page=48
Chemical properties
Technical inquiry about: 3D-PP47691 H-ASGPGGGAPR-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
